- Home
- LSBK vs ZNTL Comparison
LSBK vs ZNTL Comparison
Compare LSBK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | ZNTL |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 118.3M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSBK | ZNTL |
|---|---|---|
| Price | $14.76 | $1.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 11.5K | ★ 766.1K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 105.28 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $27,774,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $1.01 |
| 52 Week High | $16.95 | $3.33 |
Technical Indicators
Market Signals| Indicator | LSBK | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 45.25 |
| Support Level | $14.53 | $1.33 |
| Resistance Level | $14.98 | $1.46 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 34.85 | 21.87 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.